Is Vistagen Therapeutics, Inc. (VTGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.3% / 30% | 334.3% / 30% | 0.0% / 30% | 937.65% / 5% | ✗ NOT HALAL |
| DJIM | 6.3% / 33% | 334.3% / 33% | 0.0% / 33% | 937.65% / 5% | ✗ NOT HALAL |
| MSCI | 1.8% / 33% | 95.4% / 33% | 0.0% / 33% | 937.65% / 5% | ✗ NOT HALAL |
| S&P | 6.3% / 33% | 334.3% / 33% | 0.0% / 33% | 937.65% / 5% | ✗ NOT HALAL |
| FTSE | 1.8% / 33% | 95.4% / 33% | 0.0% / 50% | 937.65% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -6450.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -101.6% | |
| Return on Assets (ROA) | -55.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$42M |
| Free Cash Flow | -$42M |
| Total Debt | $2M |
| Debt-to-Equity | 2.8 |
| Current Ratio | 4.7 |
| Total Assets | $84M |
Price & Trading
| Last Close | $0.60 |
| 50-Day MA | $0.59 |
| 200-Day MA | $2.43 |
| Avg Volume | 1.1M |
| Beta | 0.3 |
|
52-Week Range
$0.43
| |
About Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vistagen Therapeutics, Inc. (VTGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vistagen Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vistagen Therapeutics, Inc.'s debt ratio?
Vistagen Therapeutics, Inc.'s debt ratio is 6.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.8%.
What are Vistagen Therapeutics, Inc.'s key financial metrics?
Vistagen Therapeutics, Inc. has a market capitalization of $23M, and revenue of $486,000. Return on equity stands at -101.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.